This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:osteoarthritis [01.05.2019] – [Introduction] sallieq | home:diseases:osteoarthritis [01.05.2019] – [Research] sallieq | ||
---|---|---|---|
Line 11: | Line 11: | ||
===== Evidence of infectious cause ===== | ===== Evidence of infectious cause ===== | ||
- | Since studies are now showing that tetracycline can slow down the OA process, this suggests that this process is caused | + | Since studies are now showing that tetracycline can slow down the OA process, this suggests that this process is impacted |
- | The almost universal use of methotrexate and the rapid development of potent biologic agents have eclipsed the potential usage of TETs for RA. Ironically, it is in osteoarthritis, | + | < |
Line 53: | Line 53: | ||
Altogether, our data show that tetracyclines have no inhibitory potential on any proteoglycanolytic activities within mild or moderately affected human OA cartilage at therapeutic achievable plasma levels. | Altogether, our data show that tetracyclines have no inhibitory potential on any proteoglycanolytic activities within mild or moderately affected human OA cartilage at therapeutic achievable plasma levels. | ||
+ | |||
+ | Biomarkers of early stage osteoarthritis, | ||
| | ||
{{tag> | {{tag> |